ZyVersa Therapeutics (ZVSA) 10-Q 12 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 10, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-41184
Entity Registrant Name	ZYVERSA THERAPEUTICS, INC.
Entity Central Index Key	0001859007
Entity Tax Identification Number	86-2685744
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2200 N. Commerce Parkway
Entity Address, Address Line Two	Suite 208
Entity Address, City or Town	Weston
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33326
City Area Code	(754)
Local Phone Number	231-1688
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ZVSA
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		20,225,263

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor
Current Assets:
Cash	$ 1,278,073	$ 5,902,199
Prepaid expenses and other current assets	1,321,551	225,347
Vendor deposits	235,000	235,000
Total Current Assets	2,834,624	6,362,546
Equipment, net	14,733	17,333
In-process research and development	100,086,329	100,086,329
Goodwill	11,895,033	11,895,033
Security deposit	46,659	46,659
Operating lease right-of-use asset	76,324	98,371
Total Assets	114,953,702	118,506,271
Current Liabilities:
Accounts payable	6,381,086	6,025,645
Accrued expenses and other current liabilities	2,112,812	2,053,559
Operating lease liability	84,507	108,756
Total Current Liabilities	8,578,405	8,187,960
Deferred tax liability	9,276,932	10,323,983
Total Liabilities	17,855,337	18,511,943
Commitments and contingencies (Note 7)
Redeemable common stock, subject to possible redemption		331,331
Stockholders’ Equity:
Common stock, value	922	902
Additional paid-in-capital	105,562,569	104,583,271
Accumulated deficit	(8,465,128)	(4,921,178)
Total Stockholders’ Equity	97,098,365	99,662,997
Total Liabilities, Temporary Equity and Stockholders’ Equity	114,953,702	118,506,271
Series A Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock, value	1	1
Series B Preferred Stock [Member]
Stockholders’ Equity:
Preferred stock, value	$ 1	$ 1

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Successor
Temporary equity, shares outstanding	0	65,783
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	110,000,000	110,000,000
Common stock, shares issued	9,211,922	9,016,139
Common stock, shares outstanding	9,211,922	9,016,139
Series A Preferred Stock [Member]
Preferred stock, shares authorized	8,635	8,635
Preferred stock, shares issued	8,635	8,635
Preferred stock, shares outstanding	8,635	8,635
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5,062	5,062
Preferred stock, shares issued	5,062	5,062
Preferred stock, shares outstanding	5,062	5,062

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor
Operating Expenses:
Research and development	$ 1,055,943
General and administrative	3,536,136
Total Operating Expenses	4,592,079
Loss From Operations	(4,592,079)
Other (Income) Expense:
Interest (income) expense	(1,078)
Change in fair value of derivative liabilities
Pre-Tax Net Loss	(4,591,001)
Income tax benefit	1,047,051
Net Loss	$ (3,543,950)
Net Loss Per Share
- Basic and Diluted	$ (0.39)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted	9,128,488
Predecessor [Member]
Financial Designation, Predecessor and Successor [Fixed List]		Predecessor
Operating Expenses:
Research and development		$ 1,066,962
General and administrative		2,301,369
Total Operating Expenses		3,368,331
Loss From Operations		(3,368,331)
Other (Income) Expense:
Interest (income) expense		168,064
Change in fair value of derivative liabilities		212,100
Pre-Tax Net Loss		(3,748,495)
Income tax benefit
Net Loss		$ (3,748,495)
Net Loss Per Share
- Basic and Diluted		$ (0.16)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted		24,167,257

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) - USD ($)		Total	Predecessor [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Predecessor [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member] Predecessor [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Predecessor [Member]	Retained Earnings [Member]	Retained Earnings [Member] Predecessor [Member]
Balance at Dec. 31, 2021			$ (12,831,466)					$ 242		$ 40,065,109		$ (52,896,817)
Balance, shares at Dec. 31, 2021								24,167,257
Financial Designation, Predecessor and Successor [Fixed List]		Predecessor	Predecessor
Stock-based compensation			$ 1,941,746							1,941,746
Net loss			(3,748,495)									(3,748,495)
Issuance of preferred stock in private placement	[1]		393,301		$ 1					393,300
Issuance of preferred stock in private placement, shares	[1]				133,541
Balance at Mar. 31, 2022			(14,244,914)		$ 1			$ 242		42,400,155		(56,645,312)
Balance, shares at Mar. 31, 2022					133,541			24,167,257
Balance at Dec. 31, 2021			$ (12,831,466)					$ 242		$ 40,065,109		$ (52,896,817)
Balance, shares at Dec. 31, 2021								24,167,257
Financial Designation, Predecessor and Successor [Fixed List]		Successor
Balance at Dec. 31, 2022		$ 99,662,997		$ 1		$ 1	$ 902		$ 104,583,271		$ (4,921,178)
Balance, shares at Dec. 31, 2022				8,635		5,062	9,016,139
Financial Designation, Predecessor and Successor [Fixed List]		Successor
Reclassification of formerly redeemable common stock		$ 331,331					$ 7		331,324
Reclassification of formerly redeemable common stock, shares							65,783
Issuance of common stock pursuant to vendor agreements		395,200					$ 13		395,187
Issuance of common stock pursuant to vendor agreements, shares							130,000
Registration costs associated with preferred stock issuance		(34,674)							(34,674)
Stock-based compensation		287,461							287,461
Net loss		(3,543,950)									(3,543,950)
Balance at Mar. 31, 2023		$ 97,098,365		$ 1		$ 1	$ 922		$ 105,562,569		$ (8,465,128)
Balance, shares at Mar. 31, 2023				8,635		5,062	9,211,922
[1]Includes gross proceeds of $ 419,320 26,019

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) (Unaudited) (Parenthetical) - Predecessor [Member]	3 Months Ended
	Mar. 31, 2022 USD ($)
Gross proceeds	$ 419,320
Issuance costs	$ 26,019

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor	Successor
Cash Flows From Operating Activities:
Net loss	$ (3,543,950)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	287,461
Amortization of debt discount
Change in fair value of derivative liability
Depreciation of fixed assets	2,600
Non-cash rent expense	22,047
Deferred tax benefit	(1,047,051)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(701,004)
Vendor deposits
Accounts payable	355,441
Operating lease liability	(24,249)
Accrued expenses and other current liabilities	59,253
Net Cash Used In Operating Activities	(4,589,452)
Cash Flows From Financing Activities:
Proceeds from issuance of preferred stock in private placement
Registration and issuance costs associated with preferred stock issuance	(34,674)
Net Cash (Used In) Provided By Financing Activities	(34,674)
Net (Decrease) Increase in Cash	(4,624,126)
Cash - Beginning of Period	5,902,199
Cash - End of Period	1,278,073		$ 5,902,199
Supplemental Disclosures of Cash Flow Information:
Reclassification of formerly redeemable common stock	331,331
Issuance of common stock pursuant to vendor agreements	395,200
Recognition of ROU asset and lease liability upon adoption of ASC 842
Predecessor [Member]
Financial Designation, Predecessor and Successor [Fixed List]		Predecessor
Cash Flows From Operating Activities:
Net loss		$ (3,748,495)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		1,941,746
Amortization of debt discount		32,184
Change in fair value of derivative liability		212,100
Depreciation of fixed assets		2,600
Non-cash rent expense		20,580
Deferred tax benefit
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(420,363)
Vendor deposits		60,000
Accounts payable		1,234,577
Operating lease liability		(22,027)
Accrued expenses and other current liabilities		313,148
Net Cash Used In Operating Activities		(373,950)
Cash Flows From Financing Activities:
Proceeds from issuance of preferred stock in private placement		419,319
Registration and issuance costs associated with preferred stock issuance		(26,019)
Net Cash (Used In) Provided By Financing Activities		393,300
Net (Decrease) Increase in Cash		19,350
Cash - Beginning of Period		328,581	$ 328,581
Cash - End of Period		347,931
Supplemental Disclosures of Cash Flow Information:
Reclassification of formerly redeemable common stock
Issuance of common stock pursuant to vendor agreements
Recognition of ROU asset and lease liability upon adoption of ASC 842		$ 182,732

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	Note 1 – Business Organization, Nature of Operations and Basis of Presentation Organization and Operations Larkspur Health Acquisition Corp. (“Larkspur”), a blank-check special purpose acquisition company, was incorporated in Delaware on March 17, 2021. On December 12, 2022, Larkspur consummated the Business Combination (as defined below) with ZyVersa Therapeutics, Inc. (“Predecessor”) which was incorporated in the State of Florida on March 11, 2014 as Variant Pharmaceuticals, Inc. Pursuant to the terms of the Business Combination Agreement (the “Business Combination Agreement”) (and upon all other conditions of the Business Combination Agreement being satisfied or waived), on the date of the consummation (the “Closing Date”) of the Business Combination and transactions contemplated thereby (the “Business Combination”), Larkspur (“New Parent”) changed its name to ZyVersa Therapeutics, Inc. and the Predecessor changed its name to ZyVersa Therapeutics Operating, Inc. (the “Operating Company”) after merging with a subsidiary of the New Parent, with the Operating Company being the surviving entity, which resulted in it being incorporated in Delaware and it being a wholly-owned subsidiary of the New Parent (collectively the “Successor”). References to the “Company” or “ZyVersa” refer to the Successor for the three months ended March 31, 2023, and to the Predecessor for the three months ended March 31, 2022. ZyVersa is a clinical stage biopharmaceutical company leveraging proprietary technologies to develop first-in-class drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The Company’s mission is to develop drugs that optimize health outcomes and improve patients’ quality of life. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of March 31, 2023 and for the three months ended March 31, 2023 and 2022. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the operating results for the full year. It is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2023. The accompanying unaudited condensed consolidated financial statements have been derived from the accounting records of the Company and its consolidated subsidiaries. As a result of the Business Combination, for accounting purposes, Larkspur Health Acquisition Corp. was the acquirer and ZyVersa Therapeutics, Inc. was the acquiree and accounting predecessor. Therefore, the financial statement presentation includes the financial statements of the Predecessor for the periods prior to December 13, 2022 and the Successor for the periods including and after December 13, 2022, including the consolidation of ZyVersa Therapeutics Operating, Inc. All significant intercompany balances have been eliminated in the unaudited condensed consolidated financial statements. The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and pursuant to the accounting rules and regulations of the SEC. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements

Going Concern and Management_s

Going Concern and Management’s Plans	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management’s Plans	Note 2 - Going Concern and Management’s Plans The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the classification of liabilities that might be necessary should the Company be unable to continue as a going concern. As of March 31, 2023, the Company had cash of approximately $ 1.3 5.7 3.5 4.6 8.5 The Company has not yet achieved profitability and expects to continue to incur cash outflows from operations. It is expected that its research and development and general and administrative expenses will continue to increase and, as a result, the Company will eventually need to generate significant product revenues to achieve profitability. Consequently, the Company will be required to raise additional funds through equity or debt financing. Management believes that the Company has access to capital resources and continues to evaluate additional financing opportunities; however, and there can be no assurance that it will be successful in securing additional capital or that the Company will be able to obtain funds on commercially acceptable terms, if at all. There is also no assurance that the amount of funds the Company might raise will enable the Company to complete its development initiatives or attain profitable operations. The aforementioned conditions raise substantial doubt about the Company’s ability to continue as a going concern for at least one year from the issuance date of these financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Since the date the Company’s December 31, 2022 financial statements were issued in its 2022 Annual Report on Form 10-K, there have been no material changes to the Company’s significant accounting policies. Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share FinancialDesignationPredecessorAndSuccessorFixedList 2023 2022 Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, 2023 2022 Predecessor warrants [1] - 2,154,352 Successor warrants [1] [5] 8,628,695 - Predecessor options - 9,947,968 Successor options 2,106,235 - Successor Series A Convertible Preferred Stock 863,500 (3) - Successor Series B Convertible Preferred Stock 506,264 (4) - Predecessor convertible notes payable [2] - 3,726,571 Total potentially dilutive shares 12,104,694 15,828,891 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 600,000 119,125 Successor [2] The Company’s convertible notes payable have embedded conversion options that result in the automatic issuance of common stock upon the consummation of certain qualifying transactions. The conversion price is a function of the implied common stock price associated with the qualifying transaction. For the purpose of disclosing the potentially dilutive securities in the table above, we used the number of shares of common stock issuable if a qualifying transaction occurred with an implied common stock price equal to the fair value of the common stock of $ 3.00 [3] Does not include an additional 3,454,000 2.00 [4] Does not include an additional 216,970 7.00 [5] Does not include an additional 3,454,000 2.00 ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements Segment Reporting The Company operates and manages its business as one reportable and operating segment. All assets and operations are in the U.S. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following as of March 31, 2023 and December 31, 2022: Schedule of Accrued Expenses and Other Current Liabilities March 31, December 31, 2023 2022 L&F milestone payment liability $ 500,000 $ 1,500,000 L&F Note [1] - (351,579 ) L&F, net 500,000 1,148,421 Payroll accrual 291,552 584,226 Other accrued expenses 51,968 214,229 Federal income tax payable 106,683 106,683 Bonus accrual 764,590 - Registration delay liability [2] 398,019 - Total accrued expenses and other current liabilities $ 2,112,812 $ 2,053,559 [1] See Note 7 – Commitments and Contingencies for details of the forgiveness of the L&F Note. [2] See Note 8 – Stockholders’ Permanent and Temporary Equity for details of the registration delay liability.

Derivative Liabilities

Derivative Liabilities	3 Months Ended
	Mar. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	Note 5 – Derivative Liabilities As of January 1, 2022, the Company had Level 3 derivative liabilities that were measured at fair value at issuance, related to the redemption features and put options of certain convertible notes. The redemption features were valued using a combination of a discounted cash flow and a Black-Scholes valuation technique. There were no During the three months ended March 31, 2022, the Predecessor recorded a gain on the change in the fair value of the derivative liabilities of $ 212,100 ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 6 – Income Taxes Income tax expense and the effective tax rate were as follows: Schedule of Income Tax Expense and the Effective Tax Rate Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, (in thousands) 2023 2022 Income tax benefit $ 1,047,051 $ - Effective tax rate 22.81 % 0.00 % The tax provisions for the three months ended March 31, 2023 and 2022 were computed using the estimated effective tax rates applicable to the taxable jurisdictions for the full year. The Company’s tax rate is subject to management’s quarterly review and revision, as necessary. The Company’s effective tax rate was 22.81 0.0

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7 – Commitments and Contingencies Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records contingent liabilities resulting from such claims, if any, when a loss is assessed to be probable and the amount of the loss is reasonably estimable. License Agreements L&F Research LLC On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waives L&F’s right to terminate the L&F License or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”). 351,579 648,421 March 31, 2023 500,000 January 31, 2024 30,000,000 On March 29, 2023, the Company forgave $ 351,579 648,421 65,783 331,331 ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements Operating Leases On January 18, 2019, the Predecessor entered into a lease agreement for approximately 3,500 89,000 497,000 The Successor 38,415 38,141 A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right of Use Assets and Liabilities Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating activities $ 24,248 $ 22,028 Right-of-use assets obtained in exchange for lease obligations Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 0.84 1.84 Weighted Average Discount Rate Operating leases 6.5 % 6.5 % Future minimum payments under these operating lease agreements are as follows: Schedule of Future Minimum Payments Under Lease Amount April 1, 2023 to December 31, 2023 $ 87,054 Less: amount representing imputed interest (2,547 ) Total $ 84,507

Stockholders_ Permanent and Tem

Stockholders’ Permanent and Temporary Equity	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Stockholders’ Permanent and Temporary Equity	Note 8 – Stockholders’ Permanent and Temporary Equity Common Stock During the three months ended March 31, 2023, the Company entered into marketing agreements with two vendors in which the Company issued an aggregate of 130,000 395,200 Temporary Equity See Note 7 – Commitments and Contingencies for discussion of the movement of temporary equity to permanent equity on March 29, 2023. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements Stock-Based Compensation For the three months ended March 31, 2023 the Successor 287,461 49,455 238,006 1,941,746 307,838 1,633,908 1,595,639 1.6 Stock Options On January 27, 2023, the Company granted ten-year 100,000 Successor 184,426 three years 2.11 On March 10, 2023, the Company granted ten-year 13,000 23,770 three years 2.26 13,000 5,000 The grant date fair value of stock options granted during the three months ended March 31, 2023 and 2022 was determined using the Black Scholes method, with the following assumptions used: Schedule of Stock Options Granted Successor Predecessor Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, 2023 2022 Fair value of common stock on date of grant $ 2.11 2.23 $ 3.00 Risk free interest rate 3.53 4.27 1.68 2.42 Expected term (years) 6.00 3.53 6.00 Expected volatility 120 122 111 119 Expected dividends 0.00 0.00 ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements A summary of the option activity for the three months ended March 31, 2023 is presented below: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 1, 2023 1,993,235 $ 10.81 Granted 113,000 2.13 Exercised - - Forfeited - - Outstanding, March 31, 2023 2,106,235 $ 10.35 5.6 $ - Exercisable, March 31, 2023 1,783,531 $ 10.18 5.3 $ - The following table presents information related to stock options as of March 31, 2023: Schedule of Information Related to Stock Options Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 2.11 100,000 - - $ 2.26 13,000 - - $ 5.03 662,887 2.8 662,887 $ 11.33 12,186 9.3 12,186 $ 11.58 728,430 6.0 723,576 $ 16.36 589,732 8.1 384,882 2,106,235 5.3 1,783,531 Effectiveness Failure In connection with the Business Combination, the Company issued 8,635 863,500 1,000 8,635,000 1.5 2.0 398,000 ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 10 – Subsequent Events Equity Offering On April 28, 2023, the Company completed an offering of 11,015,500 11,015,500 11.0 1.00 0.5 0.4 As a result of the Registered Offering, the conversion price of the 5,062 7.00 863,500 2.00 4,317,500 Redemption of PIPE Shares The proceeds from the Registered Offering were used to redeem substantially all of the original PIPE Shares for a purchase price of $ 10.1 20% 1.7 0.4 0.2 2.00

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and the amounts disclosed in the related notes to the financial statements. The Company bases its estimates and judgments on historical experience and on various other assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for, but not limited to, fair value calculations for equity securities, derivative liabilities, share based compensation and acquired intangible assets, as well as establishment of valuation allowances for deferred tax assets. Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that actual results could differ from those estimates. ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements
Net Loss Per Common Share	Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted net income per common share is computed by dividing net income by the weighted average number of common and dilutive common-equivalent shares outstanding during each period. The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share FinancialDesignationPredecessorAndSuccessorFixedList 2023 2022 Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, 2023 2022 Predecessor warrants [1] - 2,154,352 Successor warrants [1] [5] 8,628,695 - Predecessor options - 9,947,968 Successor options 2,106,235 - Successor Series A Convertible Preferred Stock 863,500 (3) - Successor Series B Convertible Preferred Stock 506,264 (4) - Predecessor convertible notes payable [2] - 3,726,571 Total potentially dilutive shares 12,104,694 15,828,891 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 600,000 119,125 Successor [2] The Company’s convertible notes payable have embedded conversion options that result in the automatic issuance of common stock upon the consummation of certain qualifying transactions. The conversion price is a function of the implied common stock price associated with the qualifying transaction. For the purpose of disclosing the potentially dilutive securities in the table above, we used the number of shares of common stock issuable if a qualifying transaction occurred with an implied common stock price equal to the fair value of the common stock of $ 3.00 [3] Does not include an additional 3,454,000 2.00 [4] Does not include an additional 216,970 7.00 [5] Does not include an additional 3,454,000 2.00 ZYVERSA THERAPEUTICS, INC. Notes to Condensed Consolidated Financial Statements
Segment Reporting	Segment Reporting The Company operates and manages its business as one reportable and operating segment. All assets and operations are in the U.S. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	The following table sets forth the outstanding potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to do so would be anti-dilutive: Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share FinancialDesignationPredecessorAndSuccessorFixedList 2023 2022 Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, 2023 2022 Predecessor warrants [1] - 2,154,352 Successor warrants [1] [5] 8,628,695 - Predecessor options - 9,947,968 Successor options 2,106,235 - Successor Series A Convertible Preferred Stock 863,500 (3) - Successor Series B Convertible Preferred Stock 506,264 (4) - Predecessor convertible notes payable [2] - 3,726,571 Total potentially dilutive shares 12,104,694 15,828,891 [1] As part of the InflamaCORE, LLC license agreement, warrants to purchase 600,000 119,125 Successor [2] The Company’s convertible notes payable have embedded conversion options that result in the automatic issuance of common stock upon the consummation of certain qualifying transactions. The conversion price is a function of the implied common stock price associated with the qualifying transaction. For the purpose of disclosing the potentially dilutive securities in the table above, we used the number of shares of common stock issuable if a qualifying transaction occurred with an implied common stock price equal to the fair value of the common stock of $ 3.00 [3] Does not include an additional 3,454,000 2.00 [4] Does not include an additional 216,970 7.00 [5] Does not include an additional 3,454,000 2.00

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following as of March 31, 2023 and December 31, 2022: Schedule of Accrued Expenses and Other Current Liabilities March 31, December 31, 2023 2022 L&F milestone payment liability $ 500,000 $ 1,500,000 L&F Note [1] - (351,579 ) L&F, net 500,000 1,148,421 Payroll accrual 291,552 584,226 Other accrued expenses 51,968 214,229 Federal income tax payable 106,683 106,683 Bonus accrual 764,590 - Registration delay liability [2] 398,019 - Total accrued expenses and other current liabilities $ 2,112,812 $ 2,053,559 [1] See Note 7 – Commitments and Contingencies for details of the forgiveness of the L&F Note. [2] See Note 8 – Stockholders’ Permanent and Temporary Equity for details of the registration delay liability.

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Income Tax Expense and the Effective Tax Rate	Income tax expense and the effective tax rate were as follows: Schedule of Income Tax Expense and the Effective Tax Rate Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, (in thousands) 2023 2022 Income tax benefit $ 1,047,051 $ - Effective tax rate 22.81 % 0.00 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Right of Use Assets and Liabilities	A summary of the Company’s right-of-use assets and liabilities is as follows: Schedule of Right of Use Assets and Liabilities Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, 2023 2022 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating activities $ 24,248 $ 22,028 Right-of-use assets obtained in exchange for lease obligations Operating leases $ - $ - Weighted Average Remaining Lease Term Operating leases 0.84 1.84 Weighted Average Discount Rate Operating leases 6.5 % 6.5 %
Schedule of Future Minimum Payments Under Lease	Future minimum payments under these operating lease agreements are as follows: Schedule of Future Minimum Payments Under Lease Amount April 1, 2023 to December 31, 2023 $ 87,054 Less: amount representing imputed interest (2,547 ) Total $ 84,507

Stockholders_ Permanent and T_2

Stockholders’ Permanent and Temporary Equity (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Schedule of Stock Options Granted	The grant date fair value of stock options granted during the three months ended March 31, 2023 and 2022 was determined using the Black Scholes method, with the following assumptions used: Schedule of Stock Options Granted Successor Predecessor Successor Predecessor For the Three For the Three Months Ended Months Ended March 31, March 31, 2023 2022 Fair value of common stock on date of grant $ 2.11 2.23 $ 3.00 Risk free interest rate 3.53 4.27 1.68 2.42 Expected term (years) 6.00 3.53 6.00 Expected volatility 120 122 111 119 Expected dividends 0.00 0.00
Schedule of Stock Option Activity	A summary of the option activity for the three months ended March 31, 2023 is presented below: Schedule of Stock Option Activity Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 1, 2023 1,993,235 $ 10.81 Granted 113,000 2.13 Exercised - - Forfeited - - Outstanding, March 31, 2023 2,106,235 $ 10.35 5.6 $ - Exercisable, March 31, 2023 1,783,531 $ 10.18 5.3 $ -
Schedule of Information Related to Stock Options	The following table presents information related to stock options as of March 31, 2023: Schedule of Information Related to Stock Options Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 2.11 100,000 - - $ 2.26 13,000 - - $ 5.03 662,887 2.8 662,887 $ 11.33 12,186 9.3 12,186 $ 11.58 728,430 6.0 723,576 $ 16.36 589,732 8.1 384,882 2,106,235 5.3 1,783,531

Going Concern and Management__2

Going Concern and Management’s Plans (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 1,278,073	$ 5,902,199
Working capital deficit	5,700,000
Net loss	3,543,950
Net cash used In operating activities	4,589,452
Accumulated deficit	$ 8,465,128	$ 4,921,178

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares		3 Months Ended		12 Months Ended
		Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]		Successor	Predecessor	Successor
Total potentially dilutive shares		12,104,694
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	[1]
Successor Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	[1],[2]	8,628,695
Predecessor Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares
Successor Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares		2,106,235
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	[3]	863,500
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	[4]	506,264
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	[5]
Predecessor [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]			Predecessor
Total potentially dilutive shares			15,828,891
Predecessor [Member] | Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	[1]		2,154,352
Predecessor [Member] | Successor Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	[1],[2]
Predecessor [Member] | Predecessor Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares			9,947,968
Predecessor [Member] | Successor Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares
Predecessor [Member] | Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares
Predecessor [Member] | Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares
Predecessor [Member] | Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potentially dilutive shares	[5]		3,726,571
[1]As part of the InflamaCORE, LLC license agreement, warrants to purchase 600,000 119,125 Successor 3,454,000 2.00 3,454,000 2.00 216,970 7.00 3.00

Schedule of Anti-dilutive Sec_2

Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) (Parenthetical) - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor	Successor
Fair value of common stock		$ 3
Series A Convertible Preferred Stock [Member]
Shares available for conversion	3,454,000
Conversion floor price	$ 2
Series B Convertible Preferred Stock [Member]
Shares available for conversion	216,970
Conversion floor price	$ 7
Series A Warrant Exercise [Member]
Shares available for conversion	3,454,000
Conversion floor price	$ 2
Inflamacore, LlC License Agreement [Member] | Common Stock [Member]
Warrants to purchase common shares	119,125	600,000

Schedule of Accrued Expenses an

Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)		Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
L&F milestone payment liability		$ 500,000	$ 1,500,000
L&F Note	[1]		(351,579)
L&F, net		500,000	1,148,421
Payroll accrual		291,552	584,226
Other accrued expenses		51,968	214,229
Federal income tax payable		106,683	106,683
Bonus accrual		764,590
Registration delay liability	[2]	398,019
Total accrued expenses and other current liabilities		$ 2,112,812	$ 2,053,559
[1]See Note 7 – Commitments and Contingencies for details of the forgiveness of the L&F Note.[2]See Note 8 – Stockholders’ Permanent and Temporary Equity for details of the registration delay liability.

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Derivative [Line Items]
Derivative liabilities	$ 0		$ 0
Change in fair value of derivative liabilities
Predecessor [Member]
Derivative [Line Items]
Change in fair value of derivative liabilities		$ 212,100

Schedule of Income Tax Expense

Schedule of Income Tax Expense and the Effective Tax Rate (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
IncomeTax [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor	Successor
Income tax benefit	$ 1,047,051
Effective tax rate	22.81%
Predecessor [Member]
IncomeTax [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]		Predecessor
Income tax benefit
Effective tax rate		0%

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
IncomeTax [Line Items]
Effective tax rate	22.81%
Predecessor [Member]
IncomeTax [Line Items]
Effective tax rate		0%

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)					3 Months Ended		12 Months Ended
	Mar. 29, 2023 USD ($) shares	Feb. 28, 2023 USD ($)	Feb. 20, 2023 USD ($)	Jan. 18, 2019 USD ($) ft²	Mar. 31, 2023 USD ($) shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) shares
CommitmentsAndContingenciesLineItems [Line Items]
Milestone payment description		On February 28, 2023, the Company and L&F executed an Amendment and Restatement Agreement that waives L&F’s right to terminate the L&F License or any other remedies, for non-payment of the First Milestone Payment, until (a) March 31, 2023 as to $1,000,000 of such milestone payments (“Waiver A”) and (b) January 31, 2024 as to $500,000 milestone payments (“Waiver B”).
Cash payment			$ 398,000
Reclassification shares of common stock | shares					0		65,783
Reclassification shares of common stock value classified as temporary to permanent equity							$ 331,331
Financial Designation, Predecessor and Successor [Fixed List]					Successor	Predecessor	Successor
Operating lease asset amortization					$ 38,415
Predecessor [Member]
CommitmentsAndContingenciesLineItems [Line Items]
Number of operating lease square feet | ft²				3,500
Lease base rent				$ 89,000
Lease base rent lease commitment				$ 497,000
Financial Designation, Predecessor and Successor [Fixed List]						Predecessor
Operating lease rent expense						$ 38,141
License Agreement [Member] | L&F Research LLC [Member] | Waiver B [Member]
CommitmentsAndContingenciesLineItems [Line Items]
Net proceeds from issuance of equity capital		$ 30,000,000
License Agreement [Member] | L&F Research LLC [Member] | Waiver A [Member]
CommitmentsAndContingenciesLineItems [Line Items]
Reclassification shares of common stock | shares	65,783
Reclassification shares of common stock value classified as temporary to permanent equity	$ 331,331
Waiver A [Member]
CommitmentsAndContingenciesLineItems [Line Items]
Debt forgiveness	351,579	351,579
Cash payment	$ 648,421	$ 648,421
Maturity date		Mar. 31, 2023
Waiver B [Member]
CommitmentsAndContingenciesLineItems [Line Items]
Cash payment		$ 500,000
Maturity date		Jan. 31, 2024

Schedule of Right of Use Assets

Schedule of Right of Use Assets and Liabilities (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
RightOfUseAssetsAndLiabilities [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor	Successor
Operating cash flows used in operating activities	$ 24,248
Operating leases
Weighted average remaining lease term	10 months 2 days
Weighted average discount rate	6.50%
Predecessor [Member]
RightOfUseAssetsAndLiabilities [Line Items]
Financial Designation, Predecessor and Successor [Fixed List]		Predecessor
Operating cash flows used in operating activities		$ 22,028
Operating leases
Weighted average remaining lease term		1 year 10 months 2 days
Weighted average discount rate		6.50%

Schedule of Future Minimum Paym

Schedule of Future Minimum Payments Under Lease (Details)	Mar. 31, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
April 1, 2023 to December 31, 2023	$ 87,054
Less: amount representing imputed interest	(2,547)
Total	$ 84,507

Schedule of Stock Options Grant

Schedule of Stock Options Granted (Details) - $ / shares	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Financial Designation, Predecessor and Successor [Fixed List]	Successor	Predecessor	Successor
Expected term (years)	6 years
Expected dividends	0%
Predecessor [Member]
Financial Designation, Predecessor and Successor [Fixed List]		Predecessor
Fair value of common stock on date of grant		$ 3
Expected dividends		0%
Minimum [Member]
Fair value of common stock on date of grant	$ 2.11
Risk free interest rate	3.53%
Expected volatility	120%
Minimum [Member] | Predecessor [Member]
Risk free interest rate		1.68%
Expected term (years)		3 years 6 months 10 days
Expected volatility		111%
Maximum [Member]
Fair value of common stock on date of grant	$ 2.23
Risk free interest rate	4.27%
Expected volatility	122%
Maximum [Member] | Predecessor [Member]
Risk free interest rate		2.42%
Expected term (years)		6 years
Expected volatility		119%

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Equity [Abstract]
Number of options, outstanding beginning balance | shares	1,993,235
Weighted average exercise price, beginning balance | $ / shares	$ 10.81
Number of options, granted | shares	113,000
Weighted average exercise price, granted | $ / shares	$ 2.13
Number of options, exercised | shares
Weighted average exercise price, exercised | $ / shares
Number of options, forfeited | shares
Weighted average exercise price, forfeited | $ / shares
Number of options, outstanding ending balance | shares	2,106,235
Weighted average exercise price, ending balance | $ / shares	$ 10.35
Weighted average remaining life in years, outstanding	5 years 7 months 6 days
Aggregate intrinsic value, ending balance | $
Number of options, exercisable ending balance | shares	1,783,531
Weighted average exercise price, Exercisable | $ / shares	$ 10.18
Weighted average remaining life in years, exercisable	5 years 3 months 18 days
Aggregate intrinsic value, exercisable | $

Schedule of Information Related

Schedule of Information Related to Stock Options (Details) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 10, 2023	Jan. 27, 2023
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price		$ 2.26	$ 2.11
Options outstanding, Number of options	2,106,235	13,000	100,000
Options exercisable, Number of options	1,783,531
Options exercisable, weighted average remaining life in life	5 years 3 months 18 days
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 2.11
Options outstanding, Number of options	100,000
Options exercisable, Number of options
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 2.26
Options outstanding, Number of options	13,000
Options exercisable, Number of options
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 5.03
Options outstanding, Number of options	662,887
Options exercisable, Number of options	662,887
Options exercisable, weighted average remaining life in life	2 years 9 months 18 days
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 11.33
Options outstanding, Number of options	12,186
Options exercisable, Number of options	12,186
Options exercisable, weighted average remaining life in life	9 years 3 months 18 days
Exercise Price Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 11.58
Options outstanding, Number of options	728,430
Options exercisable, Number of options	723,576
Options exercisable, weighted average remaining life in life	6 years
Exercise Price Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding, exercise price	$ 16.36
Options outstanding, Number of options	589,732
Options exercisable, Number of options	384,882
Options exercisable, weighted average remaining life in life	8 years 1 month 6 days

Stockholders_ Permanent and T_3

Stockholders’ Permanent and Temporary Equity (Details Narrative) - USD ($)				3 Months Ended		12 Months Ended
	Mar. 10, 2023	Feb. 20, 2023	Jan. 27, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Class of Stock [Line Items]
Shares issued	5,000
Issuance of common stock value				$ 395,200
Financial Designation, Predecessor and Successor [Fixed List]				Successor	Predecessor	Successor
Stock based compensation expense				$ 287,461
Unrecognized stock-based compensation expense				$ 1,595,639
Weighted average period				1 year 7 months 6 days
Weighted average remaining life, granted options	ten-year		ten-year
Number of options outstanding	13,000		100,000	2,106,235
Aggregate grant date value	$ 23,770		$ 184,426
Weighted average remaining life, vested options			3 years
Options outstanding, exercise price	$ 2.26		$ 2.11
Weighted average remaining life, vested options	3 years
Percentage of registration delay payments		1.50%
Interest rate		2%
Registration delay cash payment		$ 398,000
PIPE Warrant [Member]
Class of Stock [Line Items]
Number of shares issued				863,500
Number of shares issued price per share				$ 1,000
Aggregate purchase price				$ 8,635,000
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares issued				8,635
Predecessor [Member]
Class of Stock [Line Items]
Issuance of common stock value
Financial Designation, Predecessor and Successor [Fixed List]					Predecessor
Stock based compensation expense					$ 1,941,746
Research and Development Expense [Member]
Class of Stock [Line Items]
Stock based compensation expense				$ 49,455
Research and Development Expense [Member] | Predecessor [Member]
Class of Stock [Line Items]
Stock based compensation expense					307,838
General and Administrative Expense [Member]
Class of Stock [Line Items]
Stock based compensation expense				$ 238,006
General and Administrative Expense [Member] | Predecessor [Member]
Class of Stock [Line Items]
Stock based compensation expense					$ 1,633,908
Marketing Agreements [Member]
Class of Stock [Line Items]
Shares issued				130,000
Issuance of common stock value				$ 395,200

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		3 Months Ended
	Apr. 28, 2023	Mar. 31, 2023
Subsequent Event [Line Items]
Issuance costs		$ 395,200
Exercisable common stock, shares		1,783,531
Common Stock [Member]
Subsequent Event [Line Items]
Common stock offering		130,000
Issuance costs		$ 13
Subsequent Event [Member]
Subsequent Event [Line Items]
Payment to redemption of original PIPE shares amount	$ 10,100,000
Percentage of premium redemption of original PIPE	20%
Premium amount of PIPE Shares	$ 1,700,000
Payment of Effectiveness Failure amount	400,000
Remaining PIPE Shares amount	$ 200,000
Common stock floor conversion price per share	$ 2
Subsequent Event [Member] | Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Common stock offering	5,062
Floor price	$ 7
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Common stock offering	11,015,500
Purchase of warrants	11,015,500
Gross proceeds	$ 11,000,000
Floor price	$ 1
Issuance costs	$ 500,000
Placement fees	$ 400,000
Subsequent Event [Member] | Common Stock [Member] | PIPE Financing [Member]
Subsequent Event [Line Items]
Purchase of warrants	863,500
Floor price	$ 2
Exercisable common stock, shares	4,317,500